Cue Biopharma Inc (CUE) Stock Price, Quote & News

Company Profile

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a novel approach to induce and expand antigen specific Tregs for regulating disease causing autoreactive Teff cells which is in preclinical trial; and CUE-501, a treatment of autoimmune disease via anti-viral T cell-mediated depletion of B cells...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 949 2680

Website: www.cuebiopharma.com

Address:

40 Guest Street, Boston, United States

d_risk Nov. 12 at 9:55 PM

$CUE - Cue Biopharma, Inc. - 10Q - Updated Risk Factors CUE flags lower cash reserves, extended funding runway via IMSCP, evolving U.S. trade/tariff risks, and ongoing Nasdaq delisting threat with a possible reverse split on the table. #Biopharma #NasdaqDelisting #TradeTariffs #FundingStrategy #CashFlowRisk 🟢 Added 🟠 Removed https://d-risk.ai/CUE/10-Q/2025-11-12

1 · Reply

ThomasBrown991 Nov. 6 at 4:06 PM

$CUE rises slightly as investors look for innovative SaaS models. AITX drives performance through advanced ROSA deployments enhancing site protection.

0 · Reply

premarketmaker Nov. 6 at 3:31 PM

$CUE .85 premarket HOD

0 · Reply

premarketmaker Nov. 6 at 1:36 PM

$CUE another sleeper - please watch this one for move over .85/squeeze - all the key words are here - Cue Biopharma and ImmunoScape Announce Strategic Collaboration to Develop Breakthrough Cell Therapy Approach for Solid Tumors - Link ~ | Float: 76.4 M | IO: 23.86% | MC: 56.4 M

0 · Reply

makedatbread88 Nov. 6 at 1:32 PM

$CUE great news deserves $1+

1 · Reply

BigPennyStockAlerts Nov. 6 at 1:05 PM

$CUE- $0.78 (low volume) Cue Biopharma and ImmunoScape Announce Strategic Collaboration to Develop Breakthrough Cell Therapy Approach for Solid Tumors

0 · Reply

DARKP00L Nov. 6 at 1:04 PM

$CUE 08:02 on Nov. 06 2025 Cue Biopharma And ImmunoScape Announce Exclusive Collaboration And License Agreement; ImmunoScape To Cevelop A Seed-and-Boost Immunotherapy Combining Cue Biopharma's CUE-100 With ImmunoScape's TCRs #tradeideas

0 · Reply

Mastersushie1 Nov. 4 at 7:30 PM

$CUE I think we've officially breached the window for SEC compliance above $1. @InvestingDoc what is your opinion about what the future holds for CUE? Delisting? Dilution? Partnership? A new CEO comes on board and he has yet to address shareholders. We should be getting an earnings call regardless and not a word on that either. And now we are in jeopardy of being delisted.

1 · Reply

Invest2live Oct. 27 at 2:38 PM

$CODX 88% already; congrats 🎊 🎉🎈 Checkout out $ACET and $CUE

2 · Reply

Bio_Be_Dirty Oct. 22 at 10:20 PM

$CUE babies going places

0 · Reply

Cue Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 6, 2025, 8:00 AM EST - 8 days ago

Cue Biopharma and ImmunoScape Announce Strategic Collaboration to Develop Breakthrough Cell Therapy Approach for Solid Tumors

Sep 29, 2025, 9:00 AM EDT - 6 weeks ago

Cue Biopharma Announces Strategic Transition in Leadership to Further Enable Next Stage of Growth with Disruptive Autoimmune Therapeutic Candidates

Aug 21, 2025, 8:00 AM EDT - 3 months ago

Cue Biopharma to Participate in Fireside Chat at the Cantor Global Healthcare Conference

Aug 13, 2025, 8:00 AM EDT - 3 months ago

Cue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma Multiforme

Aug 12, 2025, 4:05 PM EDT - 3 months ago

Cue Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Jul 16, 2025, 8:00 AM EDT - 4 months ago

Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer

Jul 1, 2025, 4:05 PM EDT - 4 months ago

Cue Biopharma Provides Update on Most Advanced Clinical Stage Asset, CUE-101, Presented by Dr. Dimitrios Colevas at the DAVA 4th Hawaii Global Summit on Thoracic Malignancies

Jun 24, 2025, 4:48 PM EDT - 5 months ago

Cue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Company's Intention to Advance IND Submission for CUE-401 to Address Unmet Need in the Treatment of Autoimmune Disease

May 12, 2025, 4:05 PM EDT - 6 months ago

Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 8, 2025, 8:00 AM EDT - 6 months ago

Cue Biopharma to Host Virtual Investor Event on May 15, 2025

May 5, 2025, 10:00 AM EDT - 6 months ago

Cue Biopharma to Participate in Fireside Chat at the Citizens Life Sciences Conference

Apr 15, 2025, 6:12 PM EDT - 7 months ago

Cue Biopharma, Inc. (CUE) Business Update Call (Transcript)

Apr 15, 2025, 2:00 AM EDT - 7 months ago

Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases

Apr 14, 2025, 10:23 PM EDT - 7 months ago

Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering

Apr 14, 2025, 5:05 PM EDT - 7 months ago

Cue Biopharma Announces Proposed Public Offering

Apr 14, 2025, 5:02 PM EDT - 7 months ago

Cue Biopharma to Host Business Update Call and Webcast

Mar 31, 2025, 4:20 PM EDT - 8 months ago

Cue Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Nov 29, 2024, 4:30 PM EST - 1 year ago

Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 25, 2024, 8:00 AM EST - 1 year ago

Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference

Nov 14, 2024, 4:05 PM EST - 1 year ago

Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 14, 2024, 8:00 AM EST - 1 year ago

Cue Biopharma Announces Strategic Organizational Transition

Nov 8, 2024, 1:30 PM EST - 1 year ago

Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting

Oct 4, 2024, 9:00 AM EDT - 1 year ago

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

Sep 26, 2024, 11:26 PM EDT - 1 year ago

Cue Biopharma Announces Pricing of $12.0 Million Public Offering

Sep 26, 2024, 11:10 PM EDT - 1 year ago

Cue Biopharma Announces Proposed Public Offering

Sep 9, 2024, 8:00 AM EDT - 1 year ago

Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer

Aug 19, 2024, 8:17 PM EDT - 1 year ago

Cue Biopharma, Inc. (CUE) Q2 2024 Earnings Call Transcript

Aug 19, 2024, 4:05 PM EDT - 1 year ago

Cue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights

May 8, 2024, 8:00 AM EDT - 1 year ago

Cue Biopharma to Present at the 20th Annual PEGS Boston Summit

Apr 24, 2024, 10:01 AM EDT - 1 year ago

Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 8, 2024, 9:43 PM EDT - 1 year ago

Cue Biopharma, Inc. (CUE) Q4 2023 Earnings Call Transcript

Apr 8, 2024, 4:05 PM EDT - 1 year ago

Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights

Feb 29, 2024, 10:00 AM EST - 1 year ago

Cue Biopharma's Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium

Nov 22, 2023, 8:00 AM EST - 2 years ago

Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit

Nov 11, 2023, 3:32 PM EST - 2 years ago

Cue Biopharma, Inc. (CUE) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 8:00 AM EST - 2 years ago

Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in November

Nov 3, 2023, 12:00 PM EDT - 2 years ago

Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms' Tumor 1 Positive Cancers at SITC 2023

Sep 27, 2023, 9:05 AM EDT - 2 years ago

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Sep 26, 2023, 8:00 AM EDT - 2 years ago

Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA®

Aug 9, 2023, 10:23 PM EDT - 2 years ago

Cue Biopharma, Inc. (CUE) Q2 2023 Earnings Call Transcript

Aug 9, 2023, 4:10 PM EDT - 2 years ago

Cue Biopharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Jun 7, 2023, 8:00 AM EDT - 2 years ago

Cue Biopharma to Host Investor Call

Jun 5, 2023, 8:00 AM EDT - 2 years ago

Cue Biopharma to Present at the Jefferies 2023 Global Healthcare Conference

May 25, 2023, 5:00 PM EDT - 2 years ago

Cue Biopharma Presents Positive Data Update from Ongoing Phase 1 Trials of CUE-101 for Recurrent/Metastatic HPV+ Head and Neck Squamous Cell Carcinoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

May 9, 2023, 4:35 PM EDT - 2 years ago

Cue Biopharma Reports First Quarter 2023 Financial Results and Recent Business Highlights

May 8, 2023, 8:00 AM EDT - 2 years ago

Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference

Apr 12, 2023, 8:00 AM EDT - 2 years ago

Cue Biopharma Welcomes Industry Veteran Mr. Patrick Verheyen to its Board of Directors

Mar 21, 2023, 11:00 PM EDT - 2 years ago

Cue Biopharma, Inc. (CUE) Q4 2022 Earnings Call Transcript

Mar 21, 2023, 4:10 PM EDT - 2 years ago

Cue Biopharma Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

d_risk Nov. 12 at 9:55 PM

1 · Reply

ThomasBrown991 Nov. 6 at 4:06 PM

$CUE rises slightly as investors look for innovative SaaS models. AITX drives performance through advanced ROSA deployments enhancing site protection.

0 · Reply

premarketmaker Nov. 6 at 3:31 PM

$CUE .85 premarket HOD

0 · Reply

premarketmaker Nov. 6 at 1:36 PM

0 · Reply

makedatbread88 Nov. 6 at 1:32 PM

$CUE great news deserves $1+

1 · Reply

BigPennyStockAlerts Nov. 6 at 1:05 PM

$CUE- $0.78 (low volume) Cue Biopharma and ImmunoScape Announce Strategic Collaboration to Develop Breakthrough Cell Therapy Approach for Solid Tumors

0 · Reply

DARKP00L Nov. 6 at 1:04 PM

0 · Reply

Mastersushie1 Nov. 4 at 7:30 PM

1 · Reply

Invest2live Oct. 27 at 2:38 PM

$CODX 88% already; congrats 🎊 🎉🎈 Checkout out $ACET and $CUE

2 · Reply

Bio_Be_Dirty Oct. 22 at 10:20 PM

$CUE babies going places

0 · Reply

Invest2live Oct. 21 at 2:55 PM

$SPRO 73% already; checkout $IBIO and $CUE

0 · Reply

Invest2live Oct. 21 at 1:53 PM

$CLYM $IBIO $NGD $IBIO 50% already; congrats 🎊 🌿🎈 Checkout $CLYM and $CUE and $LCTX

0 · Reply

Tumble51 Oct. 21 at 10:47 AM

$ACAD $BIVI $CUE $INMB $KPTI kryptonite here is Choung !!! The CEO

0 · Reply

Invest2live Oct. 16 at 4:32 PM

$NGD 1010% already; congrats 🎉 🎈🎊 Like if you still kept the shares; check out $CUE and $IPSC; do your DD and get in. Remember that these are biotech stocks and don’t put all your eggs in one basket.

0 · Reply

Invest2live Oct. 15 at 5:59 PM

$BITF 512% already; congrats 🎈 🎉🎊 Checkout $IBIO and $CUE; do your DD and get in.

0 · Reply

BadyBady Oct. 15 at 12:33 PM

$IOBT 😎😍😍😍 $CUE $TNYA

0 · Reply

BadyBady Oct. 15 at 9:11 AM

$IOBT BooooM CC: $TNYA $CUE $EZGO

1 · Reply

CalculatedSwing Oct. 15 at 1:14 AM

$BIVI 🚀 $BIVI is primed for liftoff! Phase 2b Parkinson's data incoming + liver Fast Track = massive catalysts ahead. Low float bio with 500% potential—don't sleep! Watching peers $CUE $INMB $ACAD $KPTI for sector rotation. #Biotech #BIVI

2 · Reply

Invest2live Oct. 14 at 1:48 PM

$GNPX 14% already; congrats 🎈 🎊🎉 Movement in the correct direction. Checkout $HRMY and $CUE

1 · Reply

Invest2live Oct. 13 at 8:14 PM

$PLX 153% already; congrats 🎉 🎈🎊 Checkout $CUE and $CLYM

0 · Reply

Invest2live Oct. 13 at 7:03 PM

$BITF 412% already; congrats 🎈🎉🎊 Checkout $CUE and $LCTX

1 · Reply

BadyBady Oct. 13 at 2:01 PM

$CUE Toward 1$ 😎

0 · Reply

Market Cap	51.30M
Revenue (ttm)	9.29M
Net Income (ttm)	-40.67M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-437.78%
Debt to Equity Ratio	0.14

Volume	154,700
Avg Vol	294,020
Day's Range	N/A - N/A
Shares Out	76.85M
Stochastic %K	18%
Beta	1.49
Analysts	Strong Sell
Price Target	$4.00